OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
Advanced Liver Cancer
BIOLOGICAL: OH2 injection
DLTs (Dose Limiting Toxicity), Toxic reactions according to the NCI-CTCAE 5.0 grading standard that occur within 3 weeks from the first administration, are judged to be drug-related by the investigator, and meet the non-hematological toxicity and hematological toxicity conditions specified in the clinical protocol, 3 weeks from the first administration|MTD (Maximum Tolerance dose), If â‰¥2/6 subjects developed DLT, the previous dose group was MTD, 2 years
Incidence of AE (Adverse Event) and SAE (Serious Adverse Event), According to the NCI-CTCAE 5.0 grading standard, 2 years|Objective Response Rate, The assessment result is the number and proportion of subjects with complete response + partial response., 2 years|Disease Control Rate, The assessment result is the number and proportion of subjects with complete response + partial response + stable disease., 2 years|OS (Overall Survival), The overall survival for each patient receiving OH2 will be calculated., 2 years|PFS (Progression Free Survival), Time after OH2 administration to clinical and radiographic disease progression will be evaluated., 2 years|Biodistribution and viral shedding, OH2 DNA copy, 2 years|Immunogenicity, HSV-2 antibody, 2 years
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma